peptide degradation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-07-22. Anything still debated is marked as such rather than presented as settled.
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
| Property | Value | Notes |
|---|---|---|
| 外观 | 白色至类白色粉末 | 常见于冻干制剂 |
| 溶解度 | 易溶于水 | 在极性溶剂中一般也可溶 |
| 建议储存温度 | -20 °C | 冻干粉，避光密封 |
| 常见分析手段 | 反相高效液相色谱 | 常与质谱联用 |
| 主要降解路径 | 水解与氧化 | 溶液状态更显著 |
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
==== Potato syrup ==== This potato syrup replaces sugar and sugar syrup. It is used in baking. In the Netherlands, the production of potato syrup started in 1819 in Gouda where the first starch and sugar factory was built.
It has a Ki of over 10,000 nM (and thus negligible affinity) for β-adrenergic, H1, and mACh. Toxicity depends on the route of administration; the LD50s in mice were 300 mg/kg for the oral route, 160 mg/kg for intraperitoneal, and 56 mg/kg intravenous.
These four identified subtypes correlate with the consistency of the stool, which can be determined by the Bristol stool scale. In 2007, the Mayo Clinic College of Medicine in Rochester, Minnesota, United States, reported a piece of epidemiological research conducted on a population of 4,196 people living in Olmsted County Minnesota, in which participants were asked to complete a questionnaire based on the Bristol stool scale.
Most fossils of cnidarians have been found in marine paleoenvironments, which is consistent with the marine habitat of most extant cnidarian species. In the Carboniferous and Permian, some cnidarian fossils have been reported in non-marine (continental environments). These have typically been interpreted as freshwater paleoenvironments, but this is uncertain given that brackish (even hypersaline) continental water bodies exist (even outside deserts) and harbor moderate biodiversity, that continental habitat is inferred when typical marine markers are absent, and negative evidence is inherently weak, all of which led to controversies about many of these supposedly freshwater deposits. Indeed, some continental Paleozoic cnidarians are thought to have inhabited salt lakes. A study even argued that fossil medusoids (some of which have been interpreted as freshwater by other studies) are "restricted lagoonal facies where anoxia and hypersalinity fostered preservation", and another one reinterpreted fossils of Essexella that had initially been interpreted as freshwater medusae from Mazon Creek as euryhaline semi-infaunal anemone. Hydroconozoa is an extinct class of cnidarians, established by K.B. Korde in 1964 based on Lower Cambrian fossils from Tuva, USSR. These conical and cylindrical organisms, including genera like Hydroconus and Tuvaeconus, possessed external skeletons with features resembling both scyphozoans and tetracorals. Their unique skeletal structures suggest a distinct lineage within early cnidarian evolution.
Sources: en.wikipedia.org
The first selective CCKB receptor antagonists were modified peptide molecules such as CI-988 and the more metabolically stable CI-1015, however these were disadvantaged by only being able to be administered by injection and rapid breakdown inside the body, which led to a short half-life and limited utility. Non-peptide CCKB receptor antagonists such as L-365,260, L-369,293, YF-476, RP-69758, LY-288,513, PD-145,942 and the CCKB receptor inverse agonist L-740,093 have since been developed, and while all of the drugs developed so far have suffered from limited bioavailability or other issues which have hindered their clinical development, research in this area continues. CCKA receptors are also expressed in the brain to some extent, and IQM-95333, an antagonist selective for this population of CCKA receptors, was also found to reduce anxiety in animal models. Conversely, inhibition of CCKB receptors in the gut produces similar inhibition of secretion of gastric acid and pepsinogen enzymes as is seen with inhibition of CCKA receptors, suggesting that while the CCKA and CCKB receptors comprise two structurally distinct families which bind different ligands and are primarily expressed in different tissues, they produce similar effects, and the distinction between their gastrointestinal and anxiolytic actions depends mainly on where they are expressed in the body.
=== Contraindications === Ceftriaxone should not be used in those with an allergy to ceftriaxone or any component of the formulation. Although there is negligible cross-reactivity between penicillins and third-generation cephalosporins, caution should still be used when using ceftriaxone in penicillin-sensitive patients. Caution should be used in people who have had previous severe penicillin allergies. It should not be used in hyperbilirubinemic neonates, particularly those who are premature because ceftriaxone is reported to displace bilirubin from albumin binding sites, potentially causing bilirubin encephalopathy. Concomitant use with intravenous calcium-containing solutions/products in neonates (≤28 days) is contraindicated even if administered through different infusion lines due to rare fatal cases of calcium-ceftriaxone precipitations in neonatal lungs and kidneys.
== Other forms of copper sulfate == Anhydrous copper(II) sulfate can be produced by dehydration of the commonly available pentahydrate copper sulfate. In nature, it is found as the very rare mineral known as chalcocyanite. The pentahydrate also occurs in nature as chalcanthite. Other rare copper sulfate minerals include bonattite (trihydrate), boothite (heptahydrate), and the monohydrate compound poitevinite. There are numerous other, more complex, copper(II) sulfate minerals known, with environmentally important basic copper(II) sulfates like langite and posnjakite.
Sources: en.wikipedia.org
== Mechanism of action == There are several proposed mechanisms of how solanine causes toxicity in humans, but the true mechanism of action is not well understood. Solanum glycoalkaloids have been shown to inhibit cholinesterase, disrupt cell membranes, and cause birth defects. One study suggests that the toxic mechanism of solanine is caused by the chemical's interaction with mitochondrial membranes. Experiments show that solanine exposure opens the mitochondrial permeability transition pores of the inner mitochondrial membrane, decreasing the membrane potential. The opening of these pores leads to Ca2+ being transported from the mitochondria into the cytoplasm, and this increased concentration of Ca2+ in the cytoplasm triggers cell damage and apoptosis. Potato, tomato, and eggplant glycoalkaloids like solanine have also been shown to affect active transport of sodium across cell membranes. This cell membrane disruption is likely the cause of many of the symptoms of solanine toxicity, including burning sensations in the mouth, nausea, vomiting, abdominal cramps, diarrhea, internal hemorrhaging, and stomach lesions.
Following the referral, the Court of Appeal began to re-examine Norris' case in May 2025. The renewed appeal was described as being of interest to lawyers acting for Lucy Letby due to her case involving similar concerns about the reliability of insulin testing and expert evidence, though the Court of Appeal would later give an oblique warning against drawing such parallels when handing down its judgement. Norris was represented during the fourteen-day hearing by Michael Mansfield KC. The court reserved judgement on 6 June 2025 and then rejected Norris' appeal on 26 June, holding that there was "no doubt" about his conviction. Norris' lawyers subsequently attempted to have an unspecified point of law certified by the Supreme Court, but the required permission was denied by the Court of Appeal in September 2025.
It was therefore assumed that the cyclopropane ring serves as a storage for an activated methylene group to enable subsequent methylation reactions. This is contradicted by the fact that the lactobacillic acid content remains constant, at least in E. coli. The time of biosynthesis suggests that the fatty acid has a protective effect on the bacterial cells in the subsequent stationary phase. However, despite intensive research, it has not yet been possible to clarify exactly what this protective effect consists of. The composition of the fatty acids in the phospholipids of the cell membrane influences their fluidity. A replacement of cis vaccenic acid by lactobacillic acid has different effects depending on the position of the glycerol at which the fatty acid is esterified in the phosphoglyceride. Within the temperature range relevant for most living organisms, the incorporation of a fatty acid with a cyclopropane ring tends to mean that a change in temperature does not have a major influence on fluidity. The biomembrane is therefore fluid over a somewhat wider temperature range. Contrary to what the cyclopropane structure suggests, lactobacillic acid - bound in the phospholipids - is relatively stable. Compared to the unsaturated fatty acid (as a precursor in biosynthesis), it is even more stable in relation to mild oxidizing agents, such as when treated with ozone (ozonolysis) or with photochemically formed singlet oxygen.
At the highest trophic level is typically an apex predator, a consumer with no natural predators in the food chain model. When any trophic level dies, detritivores and decomposers consume their organic material for energy and expel nutrients into the environment in their waste. Decomposers and detritivores break down the organic compounds into simple nutrients that are returned to the soil. These are the simple nutrients that plants require to create organic compounds. It is estimated that there are more than 100,000 different decomposers in existence. Models of trophic levels also often model energy transfer between trophic levels. Primary consumers get energy from the producer and pass it to the secondary and tertiary consumers.
Sources: en.wikipedia.org
一般不建议常温长期保存。多数说明指向 -20 °C 冷冻避光。常温运输通常被视为短期可接受，但会加快降解风险。
公开资料对此没有统一答案。普遍建议现配现用，或冷藏并在数日内用完。含甲硫氨酸的序列更易氧化，放置时间越长风险越高。
反相高效液相色谱是最常用的手段，配合质谱确认分子量。氨基酸组成分析和肽图分析可补充序列层面的验证。
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.